SCHEMBL5887258

SCHEMBL5887258

CCOC(=O)N1CCN(c2nc(C)c3ccc(=O)n(-c4ccc(C(=O)NC5CC5)cc4)c3n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.45
GAA P10253 1/20 0.45
KDM4E B2RXH2 5/20 0.44
HPGD P15428 3/20 0.44
MAPK1 P28482 2/20 0.43
USP30 Q70CQ3 2/20 0.42
RAB9A P51151 2/20 0.42
NPC1 O15118 1/20 0.42
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TSHR P16473 2/20 0.41
CHRM2 P08172 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM3 P20309 1/20 0.40
HSD17B10 Q99714 1/20 0.40
MAPT P10636 1/20 0.40
MAPK8 P45983 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5887300 0.91 SMN1; SMN2 (0.43) ALDH1A1GAAKDM4EHPGDMAPK1
SCHEMBL5887033 0.90 MAPK8 (0.40) RAB9ANPC1SMN1; SMN2TSHRMAPT
SCHEMBL5887109 0.90 MAPT (0.39) ALDH1A1HPGDRAB9ANPC1SMN1; SMN2
SCHEMBL5887242 0.88 BRD4 (0.47)
SCHEMBL5886823 0.88 SMYD3 (0.48) HPGDMAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL5887495 0.86 MEN1 (0.46) SMN1; SMN2MAPK8
SCHEMBL5887138 0.86 SMN1; SMN2 (0.44) HPGDMAPK1RAB9ANPC1USP2
SCHEMBL5886718 0.86 CCNE1 (0.45) RAB9ANPC1MAPK8
SCHEMBL5887062 0.86 SMYD3 (0.43) ALDH1A1RAB9ANPC1SMN1; SMN2TSHR
SCHEMBL5887542 0.86 MAPK8 (0.45) ALDH1A1HPGDRAB9ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7019002-B2 Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents PHARMACIA & UPJOHN, S.P.A. (IT) 2006-03-28 US claimed
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors PHARMACIA ITALIA S.P.A. 2004-01-15 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009993-A1 Pyridopyrimidinones derivatives as telomerase inhibitors TERT, TERF2, TERF2IP ALDH1A1 1860/4885GAA 2823/4885KDM4E 840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.